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ABSTRACT
Glioblastoma is the most common primary brain tumor in adults; with a survival 
rate of 12 months from diagnosis. However, a small subgroup of patients, termed 
long-term survivors (LTS), has a survival rate longer then 12–14 months. There 
is thus increasing interest in the identification of molecular signatures predicting 
glioblastoma prognosis and in how to improve the therapeutic approach. Here, we 
report miR-340 as prognostic tumor-suppressor microRNA for glioblastoma. We 
analyzed microRNA expression in > 500 glioblastoma patients and found that although 
miR-340 is strongly down-regulated in glioblastoma overall, it is up-regulated in 
LTS patients compared to short-term survivors (STS). Indeed, miR-340 expression 
predicted better prognosis in glioblastoma patients. Coherently, overexpression of 
miR-340 in glioblastoma cells was found to produce a tumor-suppressive activity. 
We identified NRAS mRNA as a critical, direct target of miR-340: in fact, miR-340 
negatively influenced multiple aspects of glioblastoma tumorigenesis by down-
regulating NRAS and downstream AKT and ERK pathways. Thus, we demonstrate that 
expression of miR-340 in glioblastoma is responsible for a strong tumor-suppressive 
effect in LTS patients by down-regulating NRAS. miR-340 may thus represent a novel 
marker for glioblastoma diagnosis and prognosis, and may be developed into a tool 
to improve treatment of glioblastoma.
INTRODUCTION
Malignant glioma (glioblastoma or GBM) is the 
most common and aggressive primary brain tumor 
[1, 2]. Despite continuous improvement in treatment 
approaches, with a combination of surgery, radiotherapy 
and chemotherapy, average survival of GBM patients has 
improved only slightly [3]. In fact, GBM patients tend to 
have an extremely poor prognosis, with a median survival 
rate from diagnosis ranging from 12 to 14 months [4, 5]. 
Different factors are involved in GBM aggressiveness and 
poor prognosis, such as rapid cell proliferation, resistance 
to drug-induced apoptosis and enhanced invasiveness. 
Nevertheless, a small subset of patients presents a 
better outcome, surviving longer than 14 months: these 
patients are termed long-term survivors (LTS) [4]. The 
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molecular events associated with the LTS phenotype are 
not well elucidated. Better understanding of these events 
would be critical for the development of early detection 
methods, identification of new biomarkers, and improved 
therapeutic approaches. 
MicroRNAs (miRNAs or miRs) are a class of 
evolutionary conserved small non-coding RNAs that have 
great impact on a wide spectrum of biological processes. 
miRNAs act by affecting gene expression at the post-
transcriptional level [6]. Many studies have demonstrated 
a pivotal role for miRNAs in tumorigenesis, acting 
both as oncogenes or tumor suppressors [7–10]. During 
tumor initiation and progression, miRNAs may modulate 
proliferation, angiogenesis, invasion and survival [11]. 
Deregulation of miRNA expression has been found in 
many human cancers, including GBM [12–15].
NRAS is a member of the RAS oncogene family 
(which comprises KRAS, HRAS and NRAS); they encode 
small GTPases involved in cellular signal transduction. 
RAS is activated by a complex signal cascade and, in 
turn, triggers downstream signaling pathways such as the 
mitogen-activate protein kinases (MAPKs) pathway and 
the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, 
to modulate cell growth and survival [16]. Various studies 
have demonstrated recurrent aberrant NRAS activation 
in GBM [17]. Recently, several miRNAs –such as miR-
181d, let-7 and miR-143– have been reported to suppress 
RAS expression, and thus act as tumor suppressors; this 
suggests that the dysregulation of miRNAs targeting NRAS 
may have an important role in carcinogenesis [8, 18–20]. 
For the present study, we investigated differential 
miRNA expression in long- and short-term GBM 
survivors. We identified miR-340 as a novel tumor 
suppressor miRNA that is up-regulated in LTS patients 
and predictive of better prognosis. Furthermore, we 
describe the oncosuppressive mechanisms induced by 
this miRNA: its ability to directly target NRAS, and thus 
silence downstream pathways, contributed in the blunting 
of the tumorigenic behavior of GBM cells.
RESULTS
miR-340 expression correlates with survival in 
GBM patients
To identify miRNAs de-regulated in long- vs short-
term GBM survivors, we profiled the miRNA signatures 
of primary GBM tissue harvested from 3 LTS and 3 STS 
patients. The analysis was performed with a microarray 
chip containing 1150 miRNA probes, including 326 
human and 249 mouse miRNAs, spotted in duplicate. 
Data obtained indicated that seven miRNAs (namely 
miR-193b, -340, -19b, -20a-b, -219-5p, -137 and -129-
3p) were significantly de-regulated (> 1.5-fold change) in 
LTS vs STS GBM patients (Supplementary Table 1). We 
decided to focus our attention on miR-340, because we 
and others have already demonstrated the oncosuppressive 
role of this miRNA in different human tumors [21–27]. 
Accordingly with microarray data, qRT-PCR for miR-
340 confirmed that it was up-regulated in LTS patients 
(Supplementary Figure 1A). 
We then analyzed miR-340 expression in a larger 
cohort of glioblastoma patients (n = 61), as well as in data 
collected from TCGA database (491 glioblastomas and 10 
normal brain samples). As expected, miR-340 expression 
was significantly decreased in STS compared to LTS 
(p < 0.05; Figure 1A, 1B), and in GBM compared to 
normal brain (p < 0.001; Figure 1C). Furthermore, Log-
Rank analysis of two different cohorts of GBM patients 
(43 GBM patients from our hospital and 327 from TCGA) 
indicated that patients with higher levels of miR-340 had 
longer overall survival, suggestive of a prognostic role of 
miR-340 (p < 0.05; p < 0.01). The Kaplan-Meier curves of 
the patient cohorts are given in Figure 1D–1E. Interestingly, 
higher levels of RNF130, the host gene of miR-340, was 
also predictive of a better prognosis in GBM patients 
(p < 0.05; fig1f, data from R2.aml database). Finally, we 
found that miR-340 expression did not correlate with 
different glioma tumor stages (Supplementary Figure 1B) 
and with MGMT methylation status (Supplementary 
Figure 1C).
NRAS mRNA is a direct target of miR-340
To identify possible miR-340 targets involved in 
the LTS phenotype, we parsed bioinformatics databases 
(Targetscan, Miranda, Pictar). We found the presence of 
two distinct putative miR-340 binding sites on the 3′UTR 
of NRAS mRNA (Figure 2A). To assess if miR-340 
directly bound to these two putative regions, we cloned 
them individually downstream of a luciferase reporter gene 
in the pGL3 vector. A549 NSCLC cells (expressing low 
endogenous level of miR-340) [25] were co-transfected 
with the reporter plasmids singularly or in combination, 
in the presence of either miR-340 or a control miRNA 
(scrambled). Luciferase activity of both reporters was 
repressed by the addition of miR-340 (Figure 2B); 
moreover, the effect was greater in cells co-transfected 
with both reporters, indicating that the two NRAS 3′UTR 
sites acted synergistically. Luciferase activity was not 
affected by miR-340 overexpression in the presence of 
mutant constructs, in which the seed sequences were 
cloned inversely (Figure 2A–2B).
To establish a causative effect between miR-340 and 
NRAS, we transfected different GBM cell lines (U251MG, 
U87MG and AM38 cells) with miR-340 and analyzed 
NRAS levels with qRT-PCR and Western blotting. We 
chose these three cell lines because they express low 
levels of miR-340, as assessed by qRT-PCR on a panel of 
11 different GBM cell lines (Supplementary Figure 1D). 
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Figure 1: miR-340 is down-regulated in GBM and correlates with GBM prognosis. miR-340 expression was evaluated using 
three independent patient cohorts (A) FFPE tissue from 36 LTS and 25 STS GBM patients; (B) 180 LTS and 172 STS GBM patients from 
TCGA database; (C) 10 normal brain specimens and 491 GBM tissues from TCGA database. A significant increase in miR-340 expression 
was identified between LTS vs STS in both cohorts and in normal brain vs GBM tissue. miR-340 expression was assessed by Real-Time 
PCR and normalized against U6. An arbitrary cut-off of 12 months was used to divide LTS and STS patients. Statistical significance was 
calculated using Student’s t-test. P < 0.05 was considered significant. (D, E), Kaplan-Meier survival curve analysis of the correlation 
between miR-340 and overall survival of: (D) the FFPE tissues from 16 highly and 27 poorly miR-340-expressing glioblastoma patients; (E) 
140 highly and 187 poorly miR-340-expressing glioblastoma patients collected from TCGA database. High miR-340 expression predicted 
a better prognosis in both cohorts. The patients were assigned to the high or low miR-340-expressing group using the media as a threshold. 
P was calculated using Log-Rank test. P < 0.05 was considered significant. (F) Kaplan-Meier survival curve analysis of the correlation 
between RNF-130 and overall survival of 347 highly and 30 poorly RNF-130-expressing glioblastoma patients from the R2.aml database. 
High RNF-130 expression predicted a better prognosis. P was calculated using Log-Rank test. P < 0.05 was considered significant.
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We found a consistent, strong decrease in NRAS mRNA 
and protein in all cell lines transfected (Figure 2C–2D). In 
contrast, anti-miR-340 induced an increase in NRAS levels 
in T98G cells (Figure 2C–2D). Interestingly, miR-340 
overexpression was also able to decrease NRAS protein 
levels in three different breast cancer cell lines (BT-549, 
MDA-MB-231, MCF7; Figure 2E) and two NSCLC cell 
lines (A549, Calu-1; Figure 2F). Furthermore, to test the 
ability of miR-340 to specifically target NRAS mRNA, 
we verified that both sequences binding this miRNA 
were not conserved in KRAS or HRAS 3′UTRs (data not 
shown); coherently, miR-340 overexpression did not 
decrease KRAS or HRAS mRNA levels in GBM cells 
(Supplementary Figure 2A–2B). 
Effects of miR-340 in GBM cell lines
We investigated the tumor suppressive role of miR-
340 in different GBM cell lines (U251MG, U87MG and 
AM38 cells) transfected with either miR-340 or a control 
miRNA. We analyzed the effects of miR-340 on cell 
cycle, cell proliferation and soft agar growth. miR-340 
transfection induced a significant S-phase block, as 
assessed by FACS analysis after PI staining (Figure 3A, 
plots for qualitative data analysis are reported in 
Supplementary Figure 3A), and a significant decrease 
in cell proliferation, as assessed by BrdU incorporation 
(Figure 3B; plots for qualitative data analysis are reported in 
Supplementary Figure 4A) and MTT assay (Figure 3C–3E). 
In contrast, expression of anti-miR-340 in T98G cells 
increased cell proliferation 72 h after transfection (Figure 3E). 
We next investigated whether miR-340 expression had an 
impact on anchorage-independent cell growth with a soft 
agar assay. We found that miR-340 induced a reduction in 
colony formation in U251MG, U87MG and AM38 cells 
(Figure 3F). These results clearly demonstrate that miR-340 
acts as tumor suppressor in GBM by blunting cell cycle, 
proliferation and anchorage-independent cell growth.
miR-340 sensitizes GBM cells to TMZ
Because adjuvant chemotherapy with temozolomide 
is limited by the action of O-6-methylguanine-DNA 
methyltransferase (MGMT), a contributing factor for very 
poor survival in GBM patients [28], we investigated a 
possible role of miR-340 in TMZ sensitivity. MTT and 
Caspase 3/7 assays showed that miR-340 induced an 
increase in sensitivity to TMZ in all the cells analyzed 
(Figure 4A, 4B). Coherently, miR-340 overexpression 
determined an increase of apoptosis in GBM cells, 
as assessed by PARP cleavage (Figure 4C) as well as 
Annexin V assay (Figure 4D, plots for qualitative data 
analysis are reported in Supplementary Figure 5A). These 
results suggest that miR-340 expression contributes to 
the establishment of a LTS phenotype by enhancing the 
response of GBM patients to alkylating drugs.
NRAS: a key target molecule of miR-340-
mediated effects
NRAS is a key oncogene deregulated in many human 
cancers [16, 17, 29–31]. To demonstrate a causative 
link between miR-340 and NRAS, we performed rescue 
experiments, transfecting U251MG cells with miR-340 
and with a construct expressing NRAS mRNA lacking 
the 3′UTR. Levels of transfected NRAS were detected 
by Western blotting (data not shown). Interestingly, 
expression of this NRAS counteracted the effects of 
miR-340 overexpression on proliferation (Figure 5A–5B; 
plots for qualitative data analysis are reported in 
Supplementary Figure 4B), cell cycle (Figure 5C; plots 
for qualitative data analysis are reported in Supplementary 
Figure 3B) and anchorage-independent cell growth (Figure 
5D). Coherently, NRAS knock-down with a specific NRAS 
siRNA mimicked the effects of miR-340 overexpression, 
blocking cell cycle (Figure 5E; plots for qualitative data 
analysis are reported in Supplementary Figure 3C), 
decreasing the phosphorylation of ERK and AKT kinases 
(Figure 5F), and reducing proliferation (Figure 5G).
We then analyzed NRAS expression in a cohort of 39 
GBM patients: we found that NRAS was down-regulated in 
LTS vs STS patients (p < 0.05, Supplementary Figure 6A). 
Moreover, NRAS expression was higher in 542 GBM 
samples compared to 10 normal brain specimens (data 
collected from the oncomine database; p < 0.001; 
Supplementary Figure 6B). Furthermore, Log-Rank 
analysis of 28 GBM patients showed that those with 
higher levels of NRAS had shorter overall survival 
(Supplementary Figure 6C). This finding was confirmed 
by data from the R2.aml database (504 tissues; p < 0.05; 
Supplementary Figure 6D). In conclusion, the anti-tumoral 
effects of miR-340 seem, at least in part, to be mediated by 
its targeting of NRAS.
Recently, miR-340 was reported to directly target 
two important oncogenes, SKP2 and ROCK1, respectively 
in lung cancer and in osteosarcoma [22, 25, 26]. We found 
that miR-340 decreased the expression of both these 
oncogenes in three different GBM cell lines, suggesting 
that miR-340 may affect GBM tumorigenesis also by 
targeting other mRNAs (Supplementary Figure 7A). 
miR-340 blocks cell cycle and cell proliferation 
via inhibition of signaling pathways downstream 
from NRAS
AKT and ERK1/2 pathways act as major 
downstream signals of RAS, promoting multiple 
oncogenic features of RAS, such as cell proliferation 
and apoptosis resistance. We assessed the levels of 
phosphorylated (activated) forms of AKT and ERK1/2 
(p-AKT and p-ERK1/2) by Western blotting in 
glioblastoma cells transfected with miR-340 or a control 
scrambled sequence. miR-340 drastically reduced p-AKT 
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Figure 2: miR-340 targets NRAS. (A) Predicted miR-340 binding sites on 2 sites on NRAS-3′UTR (3′UTR NRAS R1 and 3′UTR 
NRAS R2) found with the MIRANDA algorithm (www.microrna.org) and the designed mutant sequences (3′UTR NRAS R1mut and 
3′UTR NRAS R2mut). (B) NRAS luciferase constructs containing wild-type or mutated NRAS-3′UTR-R1 or -R2, were co-transfected alone 
or in combination with miR-340 or a scrambled miRNA in A549 cells. Luciferase activity was measured 24 h after transfection. Reporter 
activities of cells co-transfected with the scrambled miRNA sequence have been arbitrarily set as 100. The results were obtained from three 
independent experiments and are presented as mean ± SD. In (B) P was calculated using ANOVA and adjusted for multiple comparisons 
with Bonferroni’s post hoc testing. *p < 0.05; **p < 0.01; ***p < 0.001 (over Scr). Glioblastoma cell lines (U251MG, U87MG and AM38), 
breast cancer cell lines (BT-549, MDA-MB-231 and MCF7), and NSCLC cell lines (A549 and Calu-1) were transfected with a scrambled 
miRNA sequence and miR-340, or with a scrambled anti-miR-340 sequence and anti-miR-340 in T98G cells for 72 h. Real-time PCR 
(C) and Western blotting (D–F) were performed to analyze NRAS mRNA and protein levels. Western blot analyses are from representative 
experiments. Actin was used as loading control. The experiments were repeated at least three times. In (C) the results are presented as 
mean ± SD. P was calculated using Student’s t-test. *p < 0.05; **p < 0.01.
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and p-ERK1/2 levels in U251MG, U87MG and AM38 
cells (Figure 6A). In contrast, transfection with anti-
miR-340 induced an increase in p-AKT and p-ERK1/2 in 
T98G cells (Figure 6A). Interestingly, performing a more 
comprehensive analysis of the AKT and ERK pathways, 
we found that miR-340 overexpression decreased the 
phosphorylation of other kinases of both AKT (mTOR, 
GSK3β), and ERK pathway (ELK) (Figure 6B).
Figure 3: miR-340’s effects in glioblastoma cells. Glioblastoma cell lines (U251MG, U87MG and AM38) were transfected with 
miR-340 or with a control scrambled miRNA sequence. We then analyzed: (A) cell cycle by flow cytometry after propidium iodide staining 
72 h after transfection; (B) cell proliferation by BrdU incorporation assay, 3 days after transfection; (C–E) cell proliferation by MTT 
assay, 1, 3, 5 and 7 days after transfection (3 days for AM38); (F) anchorage-independent cell growth by Soft Agar assay, 14 days after 
transfection. (E) T98G cells were transfected with anti-miR-340 or a control with scrambled anti-miRNA sequence and cell proliferation 
analyzed with MTT 3 days after transfection. miR-340 overexpression blocked cell cycle and decreased cell proliferation and anchorage-
independent cell growth. The data are representative of three independent experiments. Data are mean values ± SD from three independent 
experiments. P was calculated using Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001.
Oncotarget19537www.impactjournals.com/oncotarget
Next, we wondered whether miR-340-mediated 
blockade of cell cycle and cell proliferation was mediated 
by inhibition of AKT and ERK1/2 signaling pathways 
downstream of NRAS. To this aim, we transfected 
U251MG cells with miR-340 and two constructs 
expressing constitutively active forms of AKT (AKT+) and 
Figure 4: miR-340 increases TMZ sensitivity in glioblastoma cells. Glioblastoma cell lines (U251MG, U87MG and AM38) were 
transfected with a scrambled miRNA sequence or miR-340 for 24 h, and then treated with 300 µM TMZ for 24 h. Cell death and apoptosis 
were analyzed respectively with the MTT assay (A) and caspase assay (B), western blot analysis for PARP (C), and Annexin V assay (D). 
miR-340 overexpression promoted TMZ-induced apoptosis. Data are mean values ± SD of three independent experiments. P was calculated 
using Student’s t-test. *p < 0.05; **p < 0.01.
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ERK1 (ERK+) for 48 h, either alone or in combination. 
Levels of transfected AKT+ and ERK+ were assessed 
by Western blotting (data not shown). AKT+ and ERK+ 
were individually able to partially counter the effects of 
miR-340 on cell cycle (Figure 7A; plots for qualitative 
data analysis are reported in Supplementary Figure 3D), 
proliferation (Figure 7B), and anchorage independent cell 
growth (Figure 7C); the effects were greater when AKT+ 
Figure 5: NRAS mediates the effects of miR-340 on cell cycle, proliferation and anchorage-independent cell growth. 
U251MG cells were co-transfected with miR-340 and either a vector carrying NRAS lacking 3′UTR or a control. Exogenous NRAS 
expression partially counteracted the effects of miR-340 on proliferation (A, B), cell cycle (C), and anchorage-independent growth (D). 
Moreover, NRAS knock-down reproduced the effects of miR-340 transfection in GBM cells. U251MG, U87MG, and AM38 cells were 
transfected with a control siRNA or with a specific siRNA targeting NRAS. NRAS silencing mimicked the effects of miR-340 on cell cycle 
(E) decreased the phosphorylation of AKT and ERK (F) and reproduced the block of proliferation induced by miR-340 transfection (G). 
The experiments were repeated at least three times. Presented data are mean values ± SD of three independent experiments. Western blot 
analyses are representative experiments. Actin was used as the loading control. In (A–D) P was calculated using ANOVA and adjusted for 
multiple comparison with Bonferroni’s post hoc testing (over Empty + Scr); in (E, G) P was calculated using Student’s t-test. *p < 0.05; 
**p <0.01; ***p < 0.001; ****p < 0.0001.
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and ERK+ were co-transfected (Figure 7A–7C). These 
results further support the notion that miR-340 acts as a 
tumor suppressor in GBM by targeting NRAS and, hence, 
blunting downstream AKT and ERK1/2 pathways.
Overexpression of miR-340 inhibits GBM 
growth in vivo
To analyze the possible role of miR-340 in GBM 
tumorigenesis, we assessed the effects of miR-340 
overexpression on tumor growth in vivo. To this end, 
we stably infected U251MG cells with a lentiviral 
construct expressing either miR-340 or control sequence 
(Supplementary Figure 8A–8B). In accordance with 
previous data, miR-340 stable infected cells showed 
a reduction of proliferation and a block of cell cycle 
(Supplementary Figure 8C–8D). These cells were 
subcutaneously injected into the left flank (2 × 106 cells 
per flank) of CD1 nude mice (n = 6 animals per group). 
Tumor volume and vessel formation were measured 
weekly by HFUS and color-doppler HFUS for 3 weeks. 
Tumor volume and vessel formation generated by 
miR-340-expressing U251MG xenografts were 
significantly less compared to those of control xenografts 
(Figure 8A, 8B). Coherently, Ki67 staining of tumor 
sections indicated a decrease of cell proliferation in miR-
340-expressing U251MG xenografts (Figure 8C). 
DISCUSSION
GBM is one of the most aggressive types of 
human cancer and the most lethal form in the brain. It is 
characterized by extremely bad prognosis, with a median 
survival rate of only 12 months from diagnosis [2]. 
Figure 6: miR-340 overexpression decrease the activation of molecular pathways downstream NRAS. Glioblastoma cell 
lines (U251MG, U87MG and AM38) were transfected with a scrambled miRNA sequence or miR-340, or with a scrambled anti miRNA 
sequence or anti miR-340, in T98G cells, for 72 h. Western blotting was performed to analyze pAKT and pERK1/2 (A) and pmTOR, 
pGSK3β, and pELK protein levels (B) Western blot analyses are representative experiments. Actin was used as the loading control. The 
experiments were repeated at least three times. 
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Figure 7: Molecular pathways downstream from NRAS mediate the effects of miR-340 GBM cells. U251MG glioblastoma 
cells were co-transfected with miR-340 and dominant active mutants constructs of ERK and AKT, alone or in combination, or with control 
vector. Exogenous dominant active expression of both ERKs and AKT was able to partially counteract the effects of miR-340 on cell 
cycle (A) proliferation (B) and anchorage independent cell growth (C) The experiments were repeated at least three times. Presented data 
are mean values ± SD of three independent experiments. In (A) P was calculated using Student’s t-test. In (B, C) P was calculated using 
ANOVA and adjusted for multiple comparisons with the Bonferroni’s post hoc testing. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 
(over Empty + Scr).
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Figure 8: miR-340 inhibits the growth of glioblastoma xenografts in vivo. U251MG cells stably transduced with a lentiviral 
vector encoding miR-340 or with control particles were subcutaneously injected into the left flank of CD1 nude mice (n = 6 per group). 
Tumor volume and vessel formation were measured weekly by HFUS and color-doppler HFUS (Vevo 2100 with a 40MHz probe) for three 
weeks. Data in (A) and (B) show that treatment with miR-340 reduced glioblastoma-derived xenograft growth and vessel formation. In (B) 
P was calculated using Student’s t-test. *p < 0.05. (C) Nuclear localization of KI67 staining and HE staining of xenograft mice injected 
with U251MG-Lenti-Empty expressing cells and U251MG-Lenti-miR340 overexpressing cells. A representative area of each tissue is 
represented. Two mice for each experimental point are represented. Magnification 40x (Figure 8C).
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Interestingly, a small subgroup of patients survives longer. 
Better understanding of the specific molecular features 
underlying this LTS phenotype may lead to improved 
diagnosis, prognosis, treatment and, ultimately, survival of 
GBM patients [4]. At present, several molecular markers 
have been correlated to GBM prognosis, but they need 
further validation before they can be used in the clinical 
setting [28]. However, despite great effort over the last 
years, the cellular and molecular features of LTS have not 
been properly elucidated.
In the last decade, microRNAs have been frequently 
found deregulated in different human cancers, acting both 
as oncogenes or tumor suppressors. miRNAs are involved 
in basic cellular functions, including proliferation, cell 
death, differentiation, metabolism and, importantly, 
tumorigenesis [7–11, 13]. In addition, these noncoding 
RNAs have the capacity to target tens to hundreds of genes 
simultaneously [6]. Thus, they are attractive candidates 
as prognostic biomarkers and therapeutic tools/targets 
in cancer. Several studies have demonstrated that the 
expression of miRNAs is deregulated in gliomas [12, 14, 
15, 18] and may affect GBM tumorigenesis [32–34]. More 
importantly, several reports have established a direct link 
between miRNA signatures and GBM prognosis [35–38]. 
In the present study, we identify miR-340 as a tumor-
suppressive miRNA in GBM. Our experimental data, 
together with that obtained from TCGA database, show 
that miR-340 expression is significantly higher in LTS 
compared to STS patients, and in normal brain compared 
to GBM. Furthermore, statistical analysis revealed that 
patients with higher miR-340 expression had a longer 
survival rate and, thus, a better prognosis. Taken together, 
these data suggest that higher expression of miR-340 is a 
significant predictor of good prognosis in GBM.
Our functional studies show that overexpression 
of miR-340 in GBM cells determines a significant block 
of cell cycle, inhibition of cell proliferation, decrease of 
anchorage-independent cell growth, and an increase in 
sensitivity to TMZ. Furthermore, miR-340 directly binds 
to two different sites on the 3′UTR of NRAS mRNA to 
strongly inhibit NRAS protein expression. The RAS 
protein family consists of 4 highly homologous enzymes 
(NRAS, HRAS, KRAS4A and KRAS4B) that act as 
signaling molecules for the regulation of cell fate: they 
couple receptor activation to downstream effector 
pathways controlling different cellular responses, such 
as proliferation, resistance to therapy and survival [16]. 
Activating mutations of RAS proteins are common in 
human cancers, especially in hematopoietic cancers, 
colorectal cancer and melanoma [29–31]. In glioblastoma, 
NRAS activation could be caused by a direct mutation 
(5%) or by other alterations, such as amplification, 
overexpression of growth factor receptor or aberrations in 
other RAS pathway genes [17]. Recently, several miRNAs 
– including miR-181d, let-7 and miR-143– were reported 
to suppress RAS expression and function as tumor 
suppressors, suggesting that miRNAs targeting RAS may 
have an important role in carcinogenesis [18–20]. Our 
findings indicate that miR-340’s targeting of NRAS leads 
to a decrease in the activation of downstream pathways 
(namely AKT and ERKs). Experiments using dominant 
positive mutants of AKT and ERKs clearly show that 
both these pathways are down-regulated by a miR-340-
mediated effect in GBM. Thus, we have identified a new 
link between miR-340 and NRAS, a novel player in GBM 
tumorigenesis.
miR-340 has been shown to have a tumor-
suppressive activity also in other types of cancer. Wu 
et al. reported that miR-340 suppressed cell growth in 
breast cancer [21]; in osteosarcoma, miR-340 was found 
down-regulated compared to normal tissue, and ROCK-1 
was identified as a miR-340 target [22, 26]; Poenitzsch 
et al. demonstrated for the first time the pleiotropic 
regulation of the RAS-RAF-MAPKs pathway by miR-340 
in melanoma, which resulted in a strong tumor-suppressive 
activity [24]; Fernandez et al. characterized the tumor-
suppressive activity of miR-340 in lung cancer, where it 
mediated cell growth inhibition and apoptosis activation 
via the accumulation of p27 [25]; Yamashita et al. reported 
that miR-340 suppressed the stem-like cell function of 
glioma-initiating cells in vitro and in nude mouse brain 
– their findings indicated that miR-340 acted as a tumor 
suppressor in glioma-initiating cells, particularly affecting 
gliomagenesis and extensive tumor invasion [23]. 
Recently Huang et al. reported that miR-340 was able to 
inhibit glioblastoma tumorigenesis [27].
In the present study, we show that lentiviral 
vector-mediated overexpression of miR-340 in GBM 
cells inhibits cell growth in nude mice, suggestive of its 
possible therapeutic use.
In conclusion, we have observed for the first time 
a direct link between miR-340 expression and survival 
in GBM, demonstrating that miR-340 has a powerful 
oncosuppressive effect in vitro and in vivo. The mechanism 
is mediated, at least in part, by the targeting of NRAS and 
the consequential blunting of downstream ERKs and AKT 
pathways. We propose miR-340 as a novel biomarker for 
GBM prognosis, as well as a new therapeutic agent for the 
amelioration of GBM patient survival.
MATERIALS AND METHODS
Cells and tissue specimens
Glioblastoma cell lines T98G, U87MG, LN229 and 
LN18, breast cancer cell lines BT549, MDA-MB-231, 
MCF7, and NSCLC cell lines A549 and CALU-1 were 
obtained from American Type Culture Collection (ATCC), 
(LG Standards, Milan, Italy); U251MG, LN428, LN308, 
SF767 and A172 were kindly donated by Frank Furnari 
(La Jolla University, San Diego, CA, USA). U87MG, 
U251MG, T98G, AM38, A172, LN319, LN308, LN428, 
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SF767, MCF7 and Calu-1 were grown in Dulbecco’s 
modified eagle’s Medium, LN18 and LN229 in Advanced 
Dulbecco’s modified eagle’s Medium, and BT-549, 
MDA-MB-231 and A549 in RPMI Medium. Media were 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) –5% FBS for LN229 and LN18– 2 mM 
L-glutamine and 100 U/ml penicillin/streptomycin. All 
media and supplements were from Sigma Aldrich (Milan, 
Italy).
A total of 61 formalin-fixed, paraffin-embedded 
(FFPE) tissue samples were collected from the archives 
of the Department of Pathology, University Hospital 
of Kuopio, Finland. Among the 61 samples, survival 
information for 43 cases was available. Permission to use 
the material was obtained from the National Supervisory 
Authority for Welfare and Health of Finland, and the study 
was accepted by the ethical committee of the Northern 
Savo Hospital District, Kuopio, Finland. Informed consent 
was obtained from each subject or subject’s guardian.
TCGA data analysis
The collection of data from The Cancer Genome 
Atlas (TCGA) platform was compliant with laws and 
regulations for the protection of human subjects, and 
necessary ethical approvals were obtained. Analysis of 
all data was done using GraphPad Prism 6 (San Diego, 
CA, USA). For differential expression analysis and 
determination of the effect of miR-340 and NRAS on 
patient’s survival, we downloaded Agilent 8 × 15 miRNA 
expression (level 2) and HT_HG-U133A (level 3) along 
with clinical information from the TCGA database in April 
2014. 
Cell transfection
For transient overexpression of miRNAs and 
siRNAs, cells at 50% confluence were transfected using 
Oligofectamine (Invitrogen, Milan, Italy) and 100 nM 
of pre-miR-340, scrambled miRNA, anti-miR-340, 
scrambled anti-miRNA (Ambion®, Life Technologies), 
siNRAS or a siRNA control (Santa Cruz Biotechnologies, 
MA, USA). For transient overexpression of 4 µg of 
pcDNA3-NRAS, pcDNA3-AKT+, pcDNA3-ERK+ or 
pcDNA3, cells were transfected using X-tremeGENE 
9 DNA Transfection Reagent (Roche, Milan, Italy). 
Temozolomide (TMZ) was purchased from Sigma Aldrich 
(Milan, Italy).
RNA extraction and real-time PCR
Cell culture: Total RNA (microRNA and mRNA) 
was extracted using Trizol (Invitrogen, Milan, Italy) 
according to the manufacturer’s protocol. Tissue 
specimens: total RNA (miRNA and mRNA) from FFPE 
tissue specimens was extracted using RecoverAll Total 
Nucleic Acid isolation Kit (Ambion, Life Technologies, 
Milan, Italy) according to the manufacturer’s protocol. 
Reverse transcription of total RNA was performed 
starting from equal amounts of total RNA/sample (500 ng) 
using miScript reverse Transcription Kit (Qiagen, Milan, 
Italy) for miRNA analysis, and with SuperScript® III 
Reverse Transcriptase (Invitrogen, Milan, Italy) for mRNA 
analysis. Quantitative analysis of miR-340 and RNU6A 
(the latter as an internal reference) were performed by 
RT-PCR using specific primers (Qiagen, Milan, Italy) 
and miScript SYBR Green PCR Kit (Qiagen, Milan, 
Italy). RT-PCR was also used to assess the mRNAs 
of NRAS, KRAS, HRAS and β-actin (the latter as an 
internal reference), using iQTM SYBR Green Supermix 
(Bio-Rad, Milan, Italy). The primer sequences were: 
NRAS-Fw: 3′-CGCACTGACAATCCAGCTAA-5′; 
NRAS-Rv: 3′-TCGCCTGTCCTCATGTATTG-5′; 
K-RAS-Fw: 3′-ACTGGGGAGGGCTTTCTTTG-5′; 
K-RAS-Rv: 3′-GGCATCATCAACACCCTGTCT-5′; 
H-RAS: Fw: 3′-TATAAGCTGGTGGTGGTGGG-5′; 
H-RAS-Rv: 3′- TGATGGCAAACACACACAGG-5′; 
Act-FW: 5′-TGCGTGACATTAAGGAGAAG-3′; Act-Rv: 
5′-GCTCGTAGCTCTTCTCCA-3′. 
The reaction for detection of mRNAs was performed 
in this manner: 95°C for 5 min, 40 cycles of 95°C for 
30 s, 60°C for 30 s and 72°C for 30 s. The reaction for 
detection of miRNAs was performed in this manner: 
95°C for 15 min, 40 cycles of 94°C for 15 s, 55°C for 
30 s and 70°C for 30 s. All reactions were run in triplicate. 
The threshold cycle (CT) was defined as the fractional 
cycle number at which the fluorescence passed the fixed 
threshold. For relative quantization, the 2(−ΔΔCT) method 
was used. Experiments were carried out in triplicate for 
each data point, and data analysis was performed with 
Applied Biosystems’StepOnePlus™ Real-Time PCR 
System.
miRNA expression microarray and data analysis
From each sample, 5 µg of total RNA (from 
3 long- and 3 short-term GBM survivors) was reverse 
transcribed using biotin end-labeled random octamer 
oligonucleotide primer. Hybridization of biotin-labeled 
cDNA was performed on an Ohio State University custom 
miRNA microarray chip (OSU_CCC version 3.0), which 
contained 1150 miRNA probes, including 326 human 
and 249 mouse miRNA genes, spotted in duplicates. The 
hybridized chips were washed and processed to detect 
biotin-containing transcripts with a streptavidin-Alexa647 
conjugate and scanned on an Axon 4000B microarray 
scanner (Axon Instruments, Sunnyvale, CA, USA). Raw 
data were normalized and analyzed with GENESPRING 
7.2 software (zcomSilicon Genetics, Redwood City, 
CA, USA). Expression data were median-centered with 
the GENESPRING normalization option and with the 
BIOCONDUCTOR package (www.bioconductor.org) 
global median normalization tool, with similar results. 
Statistical comparisons were done with the GENESPRING 
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ANOVA tool, predictive analysis of microarray and the 
significance analysis of microarray software (http://www.
stat.stanford.edu/Btibs/SAM/index.html).
Establishment of glioblastoma cells stably 
expressing miR-340
Lentiviral vectors encoding an expression 
cassette containing a puromycin resistance gene, the 
green fluorescent protein (GFP) gene and the miR-340 
sequence under the hCMV promoter were purchased 
from GE Healthcare Dharmacon (Milan, Italy). U251MG 
cells were infected with the miR-340 lentiviral vector 
or with an empty, control vector (which lacked the 
miR-340 sequence) at a final concentration of 20 MOI. 
After culturing in selection media supplemented with 
puromycin, GFP was detected by fluorescence microscopy 
(original magnification 10x; scale bar 100 µm), and 
representative images were collected using the Leica 
Application Suite X (LAS X) software (Leica, Milan, 
Italy). Finally, puromycin-resistant, GFP-positive clones 
were picked.
Protein isolation and Western blotting
Cells were lysed in JS buffer (50 mM HEPES, 
pH 7.5, containing 150 mM NaCl, 1% glycerol, 1% Triton 
X-100, 1.5 mM MgCl2, 5 mM EGTA, 1 mM Na3VO4, 
and 1X protease inhibitor cocktail). Protein concentration 
was determined with the Bradford assay (BioRad, Milan, 
Italy) using bovine serum albumin as the standard, and 
equal amounts of proteins were analyzed by SDS-
PAGE (12% acrylamide). Gels were electroblotted into 
nitrocellulose membranes (G & E Healthcare, Milan, 
Italy). Membranes were blocked for 1 h with 5% non-
fat dry milk in tris-buffered saline (TBS) containing 
0.1% Tween-20, and incubated at 4°C overnight with 
the primary antibody. Detection was performed by 
peroxidase-conjugated secondary antibodies, using the 
enhanced chemiluminescence system (Thermo Euroclone, 
Milan, Italy). Primary antibodies used were: anti-NRAS, 
anti-ERK1, anti-SKP2, anti-ROCK1 (Santa Cruz 
Biotechnologies, MA, USA), anti-pP42/44, anti-pAKT, 
anti-AKT, anti-pmTOR, anti-mTOR, anti-pGSK3β, anti-
GSK3β, anti-pELK, anti-ELK (Cell Signaling, Danvers, 
MA, USA), and anti-βactin (Sigma Aldrich, Milan, Italy).
MTT assay
Cell vitality was evaluated with the CellTiter 96® 
AQueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI, USA), according to the 
manufacturer’s protocol. The assay is based on reduction of 
3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) to a 
colored product that is measured spectrophotometrically. 
After 24 h from miRNA or siRNA transfection, cells 
(1 × 103) were plated in 96-well plates in triplicate and 
incubated at 37°C in a 5% CO2 incubator. Metabolically 
active cells were detected by adding 20 μl of MTS to each 
well; after 30 min of incubation, the plates were analyzed 
on a Multilabel Counter (Bio-Rad, Richmond, VA, USA).
BrdU incorporation assay
Cell proliferation was evaluated with the In Situ Cell 
Proliferation Kit, FLUOS (Sigma Aldrich, Milan, Italy), 
according to the manufacturer’s protocol. The assay is based 
on the incorporation of BrdU only in actively proliferating 
cells. Cells were plated in p100 plates and transfected with 
miR-340 or scrambled sequence. After 72 h, proliferating 
cells were detected by adding BrdU to each plate; after 
4 h of incubation, the cells were fixed and labeled with 
anti-BrdU antibody conjugated with fluorescein for 
45 min. Then, BrdU incorporation were detected with a 
Becton Dickinson FACScan flow cytometer.
Cell cycle analysis
Cell cycle was analyzed via propidium iodide (PI) 
incorporation in permeabilized cells by flow cytometry. 
The cells (5 × 104) were washed in PBS and resuspended 
in 200 μl of a solution containing 0.1% sodium citrate, 
0.1% triton X-100 and 50 μg/ml propidium 6 iodide 
(Sigma Aldrich, Milan, Italy). Following incubation at 
4°C for 30 min in the dark, nuclei were analyzed with 
a Becton Dickinson FACScan flow cytometer. Cellular 
debris was excluded from analyses by raising the forward 
scatter threshold, and the DNA content of the nuclei 
was registered on a logarithmic scale. The percentage of 
elements in the hypodiploid region was calculated.
Soft-agar assay
1 × 104 cells were plated in 60mm dishes in a 
solution containing Dulbecco’s modified Eagle’s medium 
2 × (Sigma, St Louis, MO, USA), TPB buffer (Difco, 
BD, Franklin Lakes, NJ, USA), and 1.25% Noble Agar 
(Difco, BD, Franklin Lakes, NJ, USA). Briefly, cells were 
harvested and counted, then a layer of 7 ml of Noble 
Agar solution was left to polymerize on the bottom of 
the dishes. Then cells were resuspended in 2 ml of same 
solution and plated. Cells were left to grow for 2 weeks in 
the incubator.
Cell death quantification and caspase assay
Cells were transfected with miRNAs as described 
and were plated in 96-well plates in triplicate, treated, and 
incubated at 37°C in a 5% CO2 incubator. Temozolomide 
was used at a final concentration of 300 µM for 24 h. Cell 
viability was assessed using the CellTiter 96® AQueous 
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One Solution Cell Proliferation Assay (Promega, 
Madison, WI, USA), as described above. Apoptosis 
activation was analyzed with the Caspase-Glo® 3/7 Assay 
System (Promega, Madison, WI, USA), as reported in 
the instruction manual. Briefly, cells were incubated 
with medium supplemented with caspase 3/7 reagent; 
luminescence was measured following incubation for 
30 min at room temperature.
Apoptosis assessment by Annexin V staining
GBM cells were transfected with miR-340 or 
scrambled sequence. After 48 h, cells were treated with 
300 μM of TMZ for 24 h, harvested, washed twice with 
cold PBS, and stained with Annexin V-FITC Apoptosis 
Detection Kit 1 (BD Pharmingen, Milan, Italy). Briefly, 
cells were resuspended in 100 μL of 1 × binding buffer 
and 5 μL of Annexin V and then incubated for 15 min at 
room temperature. Apoptotic cells were analyzed by flow 
cytometry.
Rescue experiments
To determine whether NRAS mediated the effect of 
miR-340, rescue experiments were performed in which 
the effects of miR-340 were measured in the setting of 
overexpression of a deletion mutant of NRAS, i.e., one 
lacking the 3′ untranslated region (UTR). Cells were 
transfected with miR-340 and with the mutant NRAS 
vector, using X-tremeGENE 9 DNA Transfection Reagent 
(Roche, Milan, Italy), as described. Growth and cell cycle 
were assessed as above.
In vivo tumor formation
Five-week-old female CD1 nude mice (Charles 
River, Milan, Italy) were maintained in special pathogen 
free conditions for one week. The animal protocols used 
in this work were evaluated and approved by the Animal 
Use and Ethic Committee (OBA) of the Institute Ceinge, 
Biotecnologie Avanzate s.c.a.r.l. (Protocol 15/1/14_n 4). 
The animals protocols were performed in accordance with 
FELASA guidelines and the guidelines defined by the 
European Communities Council directive (2010/63/EU). 
The investigators adhere to widely accepted national 
standards. U251MG cells stably expressing either miR-340 
or miR-Empty were injected subcutaneously into the left 
flank of the nude mice (2 × 106 cells in 100 µl). Tumor 
size was assessed weekly with a Vevo 2100 equipment 
(FUJIFILM VisualSonics, Inc., Toronto, Ontario, Canada), 
an high-frequency ultrasound (HFUS) system mounting 
a 40 MHz probe, 1, 2, and 3 weeks after cells injection. 
The procedures were performed under general anesthesia 
with 2% isoflurane in 100% oxygen at 0.8 L/min. For each 
tumor, mediolateral, anteroposterior and craniocaudal 
diameters were measured. Tumor volume (TV) was 
calculated according to the formula V = (height × width × 
length × 3.16)/6.
Immunohistochemical staining and evaluation
Xenograft fresh frozen tissue were embedded 
in OCT compound and were cut in sections of 5 μm 
thickness. Staining was performed with an automatic 
Benchmark XT staining machine (Ventana Medical 
Systems Inc.,Tucson, AZ, USA) with an antihuman KI67 
(Ventana) antibody according to manufacture procedure. 
KI67 nuclear staining intensity was evaluated by one 
expert pathologist. For H & E staining, 2.5 µm sections 
of all fixed samples were mounted on superfrost slides 
and performed using standard methodology.
Luciferase assay
The two predicted regions on the 3′UTR of 
the human NRAS gene (R1 and R2) containing 
the putative miR-340 binding site were PCR 
amplified using the following primers: NRAS-R1-FW: 
3′-GCTCTAGATGGCATCTGCTCTAGATTCATAAA-5′; NRAS-
R1-Rv: 3′-GCTCTAGATGGCATCTGCTCTAGATTCATAAA-5′; 
NRAS-R2-FW: 3′-GCTCTAGACTATTTTAGTGGGCCCATGTT-5′; 
NRAS-R2-Rv: 3′-GCTCTAGACAAGAAGCAGAACGCACC-5′, 
and cloned downstream of the Renilla luciferase stop 
codon in a pGL3 control vector (Promega, Milan, Italy). 
An inverted sequence of the miRNA-binding sites was 
used as the negative control. A549 cells were transfected 
with miR-340 or a scrambled miRNA for 6 h. Then, the 
cells were co-transfected with 1.2 μg of 3′UTR NRAS-R1 
or -R2 plasmids, or relative mutant constructs, plus 
400 μg of a Renilla luciferase expression construct, pRL-
TK (Promega, Milan, Italy), with Lipofectamine 2000 
(Life Technologies, Milan, Italy). Cells were harvested 
24 h post-transfection, and the luciferase activity assayed 
with Dual Luciferase Assay (Promega, Milan, Italy), 
according to the manufacturer’s instructions. Three 
independent experiments were performed in triplicate.
Statistical analysis
All experiments were repeated at least three times. 
Continuous variables are given as mean ± 1 standard 
deviation (SD). For two-groups comparison, Student’s 
t-test was used to determine differences between mean 
values for normal distribution. Comparisons among more 
than two groups were determined by one-way ANOVA 
followed by Bonferroni’s post hoc testing. Survival was 
illustrated by Kaplan-Meier curves; survival differences 
between groups were examined with log-rank test. All 
data were analyzed for significance using GraphPadPrism 
6 software (San Diego, CA, USA); a probability level 
< 0.05 was considered significant throughout the 
analysis.
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